Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market is projected to reach US$ 2791.2 million in 2034, increasing from US$ 2066 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2034. Demand from Highly Emetogenic Chemotherapy and Moderately Emetogenic Chemotherapy are the major drivers for the industry.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.
North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs introduction, etc. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market is projected to reach US$ 2791.2 million in 2034, increasing from US$ 2066 million in 2022, with the CAGR of 4.3% during the period of 2024 to 2034. Demand from Highly Emetogenic Chemotherapy and Moderately Emetogenic Chemotherapy are the major drivers for the industry.
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.
North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other
Segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs introduction, etc. ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of ChemOtherapy Induced Nausea and Vomiting (CINV) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.